返回
Curing CLL: one clone at a time
DOI:10.1182/bloodadvances.2022009177.png)
摘要
En
Keyword:
IBRUTINIB
AI总结
对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
7.1
论文数:
6.1K
被引数:
2.3W
机构
引用论文
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
LEUKEMIA
IF13.4
Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia
BLOOD CANCER JOURNAL
IF11.6
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
BLOOD CANCER JOURNAL
IF11.6
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
BLOOD ADVANCES
IF7.1
没有更多内容

